References
- Zhao Q. Application value of color Doppler ultrasonography combined with tumor markers CA125 and CA724 in differential diagnosis of benign and malignant ovarian tumors. Maternal Child Health Care China. 2020;35(07:1353–5.
- Saiping H. The value of ultrasound combined with tumor markers CA125 and CA199 in the diagnosis of benign and malignant ovarian tumors. Kunming Medical College; 2009.
- Cho KR, Shih I. Ovarian cancer. Annu Rev Pathol. 2009;4:287–313. doi:https://doi.org/10.1146/annurev.pathol.4.110807.092246.
- Partridge EE, Barnes MN. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J Clin. 1999;49(5):297–320. doi:https://doi.org/10.3322/canjclin.49.5.297.
- Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–29. doi:https://doi.org/10.1056/NEJMra041842.
- Boesch M, Zeimet AG, Reimer D, Schmidt S, Gastl G, Parson W, et al. The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics. Oncotarget. 2014;5(16):7027–39. doi:https://doi.org/10.18632/oncotarget.2053.
- Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, et al. Ovarian cancer stem cells. Neoplasma. 2012;59(6):747–55. doi:https://doi.org/10.4149/neo_2012_094.
- Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11(10):719–25. doi:https://doi.org/10.1038/nrc3144.
- Kurman RJ, Shih IM. The Dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733–47. doi:https://doi.org/10.1016/j.ajpath.2015.11.011.
- Lu J, Chu X, Pan Y, Chen Y, Wen L, Dai J. Gene editing technology: advances and challenges. Proc Chinese Acad Sci. 2018;33(11):1184–92.
- Lee AH, Symington LS, Fidock DA. DNA repair mechanisms and their biological roles in the malaria parasite Plasmodium falciparum. Microbiol Mol Biol Rev. 2014;78(3):469–86. doi:https://doi.org/10.1128/MMBR.00059-13.
- Chang HHY, Pannunzio NR, Adachi N, Lieber MR. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol. 2017;18(8):495–506. doi:https://doi.org/10.1038/nrm.2017.48.
- Lieber MR, Ma Y, Pannicke U, Schwarz K. Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol. 2003;4(9):712–20. doi:https://doi.org/10.1038/nrm1202.
- Chandrasegaran S, Carroll D. Origins of programmable nucleases for genome engineering. J Mol Biol. 2016;428(5 Pt B):963–89. doi:https://doi.org/10.1016/j.jmb.2015.10.014.
- Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science. 2013; 339(6121):823–6. doi:https://doi.org/10.1126/science.1232033.
- Ayen A, Jiménez Martínez Y, Marchal JA, Boulaiz H. Recent progress in gene therapy for ovarian cancer. IJMS. 2018;19(7):1930. doi:https://doi.org/10.3390/ijms19071930.
- Paul A, Paul S. The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. Front Biosci. 2014;19:605–18. doi:https://doi.org/10.2741/4230.
- Ogishima J, Taguchi A, Kawata A, Kawana K, Yoshida M, Yoshimatsu Y, et al. The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway. BMC Cancer. 2018;18(1):1201. doi:https://doi.org/10.1186/s12885-018-4922-4.
- Wang X, Wang H, Xu B, Jiang D, Huang S, Yu H, et al. Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer. Am J Transl Res. 2019;11(2):1145–53.
- Hirschhorn T, Levi-Hofman M, Danziger O, Smorodinsky NI, Ehrlich M. Differential molecular regulation of processing and membrane expression of type-I BMP receptors: implications for signaling. Cell Mol Life Sci. 2017;74(14):2645–62. doi:https://doi.org/10.1007/s00018-017-2488-y.
- Faddaoui A, Sheta R, Bachvarova M, Plante M, Gregoire J, Renaud MC, et al. Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells. Cell Cycle. 2017;16(7):693–706. doi:https://doi.org/10.1080/15384101.2017.1295181.
- Li X, Chen W, Zeng W, Wan C, Duan S, Jiang S. microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP. Br J Cancer. 2017;116(1):66–76. doi:https://doi.org/10.1038/bjc.2016.379.
- Karthikeyan S, Russo A, Dean M, Lantvit DD, Endsley M, Burdette JE. Prolactin signaling drives tumorigenesis in human high grade serous ovarian cancer cells and in a spontaneous fallopian tube derived model. Cancer Lett. 2018;433:221–31. doi:https://doi.org/10.1016/j.canlet.2018.07.003.
- Yung MM, Tang HW, Cai PC, Leung TH, Ngu SF, Chan KK, et al. GRO-α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade. Theranostics. 2018;8(5):1270–85. doi:https://doi.org/10.7150/thno.22536.
- Sherman-Samis M, Onallah H, Holth A, Reich R, Davidson B. SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma. Gynecol Oncol. 2019;153(3):651–60. doi:https://doi.org/10.1016/j.ygyno.2019.03.099.
- Fang P, De Souza C, Minn K, Chien J. Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity. Commun Biol. 2019;2:335. doi:https://doi.org/10.1038/s42003-019-0580-6.
- Yi Y, Tsai SH, Cheng JC, Wang EY, Anglesio MS, Cochrane DR, et al. APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner. Gynecol Oncol. 2017;147(3):663–71. doi: https://doi.org/10.1016/j.ygyno.
- Zhao Q, Qian Q, Cao D, Yang J, Gui T, Shen K. Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing . J Ovarian Res. 2018;11(1):31. doi:https://doi.org/10.1186/s13048-018-0406-z.
- Cui Y, Wu BO, Flamini V, Evans BAJ, Zhou D, Jiang WG. Knockdown of EPHA1 using CRISPR/CAS9 suppresses aggressive properties of ovarian cancer cells. Anticancer Res. 2017;37(8):4415–24. doi:https://doi.org/10.21873/anticanres.11836.
- Yahata T, Mizoguchi M, Kimura A, Orimo T, Toujima S, Kuninaka Y, et al. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression. Cancer Sci. 2019; 110(4):1279–92. doi:https://doi.org/10.1111/cas.13958.
- de Groote ML, Kazemier HG, Huisman C, van der Gun BT, Faas MM, Rots MG. Upregulation of endogenous ICAM-1 reduces ovarian cancer cell growth in the absence of immune cells. Int J Cancer. 2014;134(2):280–90. doi:https://doi.org/10.1002/ijc.28375.
- Huo W, Zhao G, Yin J, Ouyang X, Wang Y, Yang C, et al. Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells. J Cancer. 2017; 8(1):57–64. doi:https://doi.org/10.7150/jca.16723.
- Zhao G, Wang Q, Gu Q, Qiang W, Wei JJ, Dong P, et al. Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells. Oncotarget. 2017; 8(55):94666–80. doi:https://doi.org/10.18632/oncotarget.21863.
- Wolf D, Fiegl H, Zeimet AG, Wieser V, Marth C, Sprung S, et al. High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome. Int J Cancer. 2020;146(7):2007–18. doi:https://doi.org/10.1002/ijc.32818.
- Liu Q, Liu H, Li L, Dong X, Ru X, Fan X, et al. ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation. Int J Oncol. 2020;56(1):219–31. doi:https://doi.org/10.3892/ijo.2019.4913.
- Chen X, Li X, Wang X, Zhu Q, Wu X, Wang X. MUC16 impacts tumor proliferation and migration through cytoplasmic translocation of P120-catenin in epithelial ovarian cancer cells: an original research. BMC Cancer. 2019;19(1):171. doi:https://doi.org/10.1186/s12885-019-5371-4.
- Ji L, Zhao G, Zhang P, Huo W, Dong P, Watari H, et al. Knockout of MTF1 inhibits the epithelial to mesenchymal transition in ovarian cancer cells. J Cancer. 2018;9(24):4578–85. doi:https://doi.org/10.7150/jca.28040.
- Norouzi-Barough L, Sarookhani M, Salehi R, Sharifi M, Moghbelinejad S. CRISPR-Cas9, a new approach to successful knockdown of ABCB1/Pglycoprotein and reversal of chemosensitivity in human epithelial ovarian cancer cell line. Iran J Basic Med Sci. 2018;21:181–7.
- Walton JB, Farquharson M, Mason S, Port J, Kruspig B, Dowson S, et al. CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Sci Rep. 2017; 7(1):16827. doi:https://doi.org/10.1038/s41598-017-17119-1.
- Kim SM, Yang Y, Oh SJ, Hong Y, Seo M, Jang M. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting. J Control Release. 2017;266:8–16. doi:https://doi.org/10.1016/j.jconrel.
- Sonego M, Pellarin I, Costa A, Vinciguerra GLR, Coan M, Kraut A, et al. USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability. Sci Adv. 2019; 5(5):eaav3235. doi:https://doi.org/10.1126/sciadv.aav3235.
- Díaz VM, Viñas-Castells R, García de Herreros A. Regulation of the protein stability of EMT transcription factors. Cell Adh Migr. 2014;8(4):418–28. doi:https://doi.org/10.4161/19336918.2014.969998.
- Huang H, Deng T, Feng Y, Liu J. Advances in the treatment of epithelial ovarian cancer. Chinese J Frontiers Med. 2020;12(05):13–7.
- Zhang Y, Mu W, Wang H. Gene editing in T cell therapy. J Genet Genomics. 2017;44(9):415–22. doi:https://doi.org/10.1016/j.jgg.
- Hardwick N, Frankel PH, Cristea M. New approaches for immune directed treatment for ovarian cancer. Curr Treat Options Oncol. 2016;17(3):14. doi:https://doi.org/10.1007/s11864-016-0389-1.
- Makvandi M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, et al. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. J Clin Invest. 2018; 128(5):2116–26. doi:https://doi.org/10.1172/JCI97992.
- Li L, Song L, Liu X, Yang X, Li X, He T, et al. Artificial virus delivers CRISPR-Cas9 system for genome editing of cells in mice. ACS Nano. 2017;11(1):95–111. doi:https://doi.org/10.1021/acsnano.6b04261.
- Li L, He ZY, Wei XW, Gao GP, Wei YQ. Challenges in CRISPR/CAS9 delivery: potential roles of nonviral vectors. Hum Gene Ther. 2015;26(7):452–62. doi: https://doi.org/10.1089/hum.
- Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65. doi:https://doi.org/10.1056/NEJMoa1200694.
- Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015–22. doi:https://doi.org/10.1200/JCO.2015.62.3397.
- Ganesh K, Massagué J.TGF-β Inhibition and Immunotherapy: Checkmate. Immunity. 2018;48(4):626–8. doi:https://doi.org/10.1016/j.immuni.2018.03.037.29669246
- Wei T, Cheng Q, Farbiak L, Anderson DG, Langer R, Siegwart DJ. Delivery of tissue-targeted scalpels: opportunities and challenges for in vivo CRISPR/Cas-based genome editing. ACS Nano. 2020;14(8):9243–62. doi:https://doi.org/10.1021/acsnano.0c04707.
- Behr M, Zhou J, Xu B, Zhang H. In vivo delivery of CRISPR-Cas9 therapeutics: progress and challenges. Acta Pharm Sin B. 2021;11(8):2150–71. doi:https://doi.org/10.1016/j.apsb.2021.05.020.
- Guo P, Yang J, Huang J, Auguste DT, Moses MA. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel. Proc Natl Acad Sci U S A. 2019;116(37):18295–303. doi:https://doi.org/10.1073/pnas.1904697116.
- Hiroko JK, Masayuki Y. Current condition of genetic medicine for hereditary breast cancer. Mol Clin Oncol. 2017;7(1):98–102. doi:https://doi.org/10.3892/mco.2017.1260.